Prospective Grant of Exclusive License: Analytical Instruments Utilizing Condensation Particle Counters for the Detection and Analysis of Small Aerosol Particles, 59798 [2015-24985]
Download as PDF
<![CDATA[
59798
Federal Register / Vol. 80, No. 191 / Friday, October 2, 2015 / Notices
Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
published under the publication rules of
either the United States Patent and
Trademark Office or the World
Intellectual Property Organization.
[FR Doc. 2015–24982 Filed 10–1–15; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Analytical Instruments
Utilizing Condensation Particle
Counters for the Detection and
Analysis of Small Aerosol Particles
Public Health Service, National
Institutes of Health, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the Public Health Service,
Department of Health and Human
Services, is contemplating the grant of
an exclusive license to Kanomax Japan,
Inc. having a principal place of business
in Osaka, Japan, to practice the
inventions embodied in U.S. Provisional
Patent Application No. 62/026,559, filed
on 18 July 2014, entitled ‘‘Aerosol
Particle Growth Systems for Personal
Sampling Applications Using Polymer
Electrolyte Membranes’’ [HHS Reference
No. E–026–2014/0–US–01]. The patent
rights in these inventions have been
assigned to the United States of
America. The territory of the
prospective exclusive patent license
may be worldwide, and the field of use
may be limited to ‘‘Analytical
instruments comprising condensation
particle counters (CPCs) for the
sampling, detection, counting and
analysis of ultrafine and nano-sized
aerosol particles.’’
DATES: Only written comments and/or
applications for a license that are
received by the NIH Office of
Technology Transfer on or before
November 2, 2015 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Tara L. Kirby, Ph.D., Chief, CDC
Unit, Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–4426; Facsimile: (301) 402–
0220; Email: tarak@mail.nih.gov. A
signed confidential disclosure
agreement may be required to receive
copies of the patent application
assuming it has not already been
mstockstill on DSK4VPTVN1PROD with NOTICES
VerDate Sep<11>2014
20:43 Oct 01, 2015
Jkt 238001
Hazardous
airborne particles pose a risk for health
and safety in a variety of environments
and thus detection of these small
particles is essential. Current particle
magnification systems are bulky and
require a lot of power for operation,
making them unsuitable to easily detect
and analyze small particles in mobile
and personal settings.
The CDC has developed space-saving
miniature instrumentation and methods
for the direct sampling and analysis of
small particles (diameter <300–400 nm).
The systems can effectively sample air
at a rate of a few liters per minute and
concentrate the particulate matter into
microliter or milliliter liquid samples.
The novel system uses proton exchange
membranes to grow small particles for
optical detection using standard
methods. Further, these methods allow
the system to separate condensation and
aerosol flow to enhance user mobility.
Moreover, the described methods use
inexpensive materials and require low
power for operation.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless, within thirty (30) days
from the date of this published notice,
the NIH Office of Technology Transfer
receives written evidence and argument
that establishes that the grant of the
contemplated license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Properly filed competing applications
for a license in the prospective field of
use that are filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Prospective Grant of Exclusive
License: Development of a ME–TARP
Based Immunotherapy
SUPPLEMENTARY INFORMATION:
BILLING CODE 4140–01–P
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–24985 Filed 10–1–15; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
National Institutes of Health
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR 404.7,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to practice
the inventions embodied in the
following U.S. Patents and Patent
Applications to PDS Biotechnology
Corporation (‘‘PDS’’) located in New
Brunswick, New Jersey, USA:
SUMMARY:
Intellectual Property
1. United States Provisional Patent
Application No. 60/476,467, filed June 5,
2003, entitled ‘‘Immunogenic Peptides
and Peptide Derivatives For The
Treatment of Prostate And Breast Cancer
Treatment’’ [HHS Reference No. E–116–
2003/0–US–01];
2. International Patent Application No. PCT/
US2004/17574 filed June 2, 2004 entitled
‘‘Immunogenic Peptides And Peptide
Derivatives For The Treatment of
Prostate And Breast Cancer Treatment’’
[HHS Reference No. E–116–2003/0–
PCT–02];
3. United States Patent No.7,541,035, issued
June 2, 2009, entitled ‘‘Immunogenic
Peptides And Peptide Derivatives For
The Treatment of Prostate And Breast
Cancer Treatment’’ [HHS Reference No.
E–116–2003/0–US–03];
4. United States Patent No. 8,043,623, issued
25 Oct 2011, entitled ‘‘Immunogenic
Peptides and Peptide Derivatives For
The Treatment of Prostate And Breast
Cancer Treatment’’ [HHS Reference No.
E–116–2003/0–US–04];
5. United States Provisional Patent
Application No. 61/915,948, filed
December 13, 2013, entitled ‘‘MultiEpitope TARP Peptide Vaccine and Uses
Thereof’’ [HHS Reference No. E–047–
2014/0–US–01];
6. International Patent Application No. PCT/
US2014/070144 filed December 12, 2014
entitled ‘‘Multi-Epitope TARP Peptide
Vaccine and Uses Thereof’’ [HHS
Reference No. E–047–2014/0–PCT–02];
and all continuation applications,
divisional applications and foreign
counterpart applications claiming
priority to the US provisional
application no. 61/915, 948.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 80, Number 191 (Friday, October 2, 2015)]
[Notices]
[Page 59798]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24985]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Analytical Instruments
Utilizing Condensation Particle Counters for the Detection and Analysis
of Small Aerosol Particles
AGENCY: Public Health Service, National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the Public Health Service, Department of Health and
Human Services, is contemplating the grant of an exclusive license to
Kanomax Japan, Inc. having a principal place of business in Osaka,
Japan, to practice the inventions embodied in U.S. Provisional Patent
Application No. 62/026,559, filed on 18 July 2014, entitled ``Aerosol
Particle Growth Systems for Personal Sampling Applications Using
Polymer Electrolyte Membranes'' [HHS Reference No. E-026-2014/0-US-01].
The patent rights in these inventions have been assigned to the United
States of America. The territory of the prospective exclusive patent
license may be worldwide, and the field of use may be limited to
``Analytical instruments comprising condensation particle counters
(CPCs) for the sampling, detection, counting and analysis of ultrafine
and nano-sized aerosol particles.''
DATES: Only written comments and/or applications for a license that are
received by the NIH Office of Technology Transfer on or before November
2, 2015 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Tara L. Kirby, Ph.D., Chief, CDC Unit, Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
4426; Facsimile: (301) 402-0220; Email: tarak@mail.nih.gov. A signed
confidential disclosure agreement may be required to receive copies of
the patent application assuming it has not already been published under
the publication rules of either the United States Patent and Trademark
Office or the World Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: Hazardous airborne particles pose a risk for
health and safety in a variety of environments and thus detection of
these small particles is essential. Current particle magnification
systems are bulky and require a lot of power for operation, making them
unsuitable to easily detect and analyze small particles in mobile and
personal settings.
The CDC has developed space-saving miniature instrumentation and
methods for the direct sampling and analysis of small particles
(diameter <300-400 nm). The systems can effectively sample air at a
rate of a few liters per minute and concentrate the particulate matter
into microliter or milliliter liquid samples. The novel system uses
proton exchange membranes to grow small particles for optical detection
using standard methods. Further, these methods allow the system to
separate condensation and aerosol flow to enhance user mobility.
Moreover, the described methods use inexpensive materials and require
low power for operation.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404. The prospective exclusive license may be granted unless, within
thirty (30) days from the date of this published notice, the NIH Office
of Technology Transfer receives written evidence and argument that
establishes that the grant of the contemplated license would not be
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Properly filed competing applications for a license in the
prospective field of use that are filed in response to this notice will
be treated as objections to the contemplated license. Comments and
objections submitted in response to this notice will not be made
available for public inspection, and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-24985 Filed 10-1-15; 8:45 am]
BILLING CODE 4140-01-P
